Resistance to traditional treatment methods is still a major obstacle in modern psychiatry. As
a result, several studies are currently being conducted to find effective alternatives to …

There has recently been a renewal of interest in psychedelic research on the use of
psilocybin in psychiatric treatment and, in particular, for the treatment of major depressive …

There is a serious need for novel therapies that treat individuals with depression, including
major depressive disorder (MDD) and treatment-resistant depression (TRD). An emerging …

Introduction There has been increasing interest in the role psilocybin may play in the
treatment of depressive disorders. Several clinical trials have shown psilocybin to have …

Background: Psilocybin is a predominant agonist of 5HT 1A and 5HT 2A/C receptors and
was first isolated in 1958, shortly before it became a controlled substance. Research on the …

The use of psychedelics, such as psilocybin, has emerged in recent literature as a novel
therapeutic treatment for various psychiatric disorders, including substance use, depression …

Abstract Psilocybin (4-phosphoryloxy-N, N-dimethyltryptamine) is an indole-based
secondary metabolite produced by numerous species of mushrooms. South American Aztec …

Psilocybin is a classic psychedelic drug that has attracted increasing research interest over
the past 10 years as a possible treatment for mood, anxiety and related conditions. Initial …

Introduction: Major depressive disorder (MDD) is a prevalent and complex mood disorder. Its
psychotherapies often involve delayed treatment-response times, while its …

Psilocybin has been suggested as a promising transdiagnostic treatment strategy for a wide
range of psychiatric disorders. Recent findings showed that psychedelic-assisted/” …